Table 1 Gefitinib, erlotinib, and fludarabine IC50 values determined by MTT assays in ZAP-70+, ZAP-70−, mutated IgVH, and unmutated IgVH primary CLL cells treated for 24 h

From: Gefitinib targets ZAP-70-expressing chronic lymphocytic leukemia cells and inhibits B-cell receptor signaling

CLL patients

Gefitinib median IC 50

Erlotinib median IC 50

Fludarabine median IC 50

ZAP-70+

4.5 μM (n=22)a

>40.0 μM (n=8)

5.4 μM (n=14)

ZAP-70−

>15.0 μM (n=23)

>40.0 μM (n=10)

7.0 μM (n=16)

Mutated (Mu-) IgVH

7.0 μM (n=26)

>40.0 μM (n=12)

7.0 μM (n=23)

Unmutated (Un-) IgVH

8.3 μM (n=13)

>40.0 μM (n=5)

5.4 μM (n=10)

ZAP-70+ and Mu-IgVH

4.0 μM (n=9)

>40.0 μM (n=2)

13.2 μM (n=6)

ZAP-70+ and Un-IgVH

6.0 μM (n=11)

>40.0 μM (n=5)

5.4 μM (n=8)

  1. aStatistical significance of gefitinib median IC50 (P<0.05) between ZAP-70+ and ZAP-70− cells.
Back to article page